STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Regeneron Pharmaceuticals (REGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Regeneron Pharma (REGN) PT Lowered to $1,120 at Jefferies
January 13, 2025 11:25 AM ESTJefferies analyst Akash Tewari lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,120.00 (from $1,200.00) while maintaining a Buy rating.
The analyst comments "REGN pre-announced Q4 #'s w/ US LD Eylea beat by ~$126m (12%) + HD miss by ~$111m (27%) & there's $85m inventory... More
